Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia
Abstract
The economics of allogeneic hematopoietic cell transplantation (alloHCT) for older patients with acute myeloid leukemia (AML) affects clinical practice and public policy. To assess reimbursement, utilization, and overall survival (OS) up to 1 year post-alloHCT for Medicare beneficiaries aged 65 years or older with AML, a unique merged dataset of Medicare claims and national alloHCT registry data was analyzed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 28, 2019
- Source ID
- 10.1093/jncics/pkz048
Entities
People
- Alicia Silver
- Christa Meyer
- David J Vanness
- Elizabeth A. Murphy
- Ellen Denzen
- Jaime M. Preussler
- Lih-wen Mau
- Linda J. Burns
- Patricia Steinert
- Susan Leppke
- Wael Saber
Organizations
- Adaptive Biotechnologies
- Center for International Blood and Marrow Transplant Research
- Health Resources and Services Administration
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Pennsylvania State University
- United States Public Health Service